Clinical Trial Costs in Latin America vs. US/EU: 2026 Benchmark Data
Comprehensive cost benchmarks for first-in-human and early feasibility studies across Latin America — with line-item breakdowns, country comparisons, and hidden cost analysis.
March 25, 2026
14
min read
By
Julio G. Martinez-Clark, CEO, bioaccess®
Clinical Trial Costs
Latin America
Cost Comparison
FIH
Budget
MedTech
"How much will my clinical trial cost?" is the question every MedTech, Biopharma, and Radiopharma sponsor asks first — and the one that's hardest to answer without context. This benchmark analysis draws on bioaccess®'s 15+ years of budget data across 50+ client programs to provide the most accurate cost comparisons available between Latin America and the US/EU for first-in-human and early feasibility studies.
**💡 Get a Personalized Estimate**
These benchmarks are industry averages. For a cost estimate tailored to your specific device, therapeutic area, and study design, use the bioaccess® Clinical Trial Calculator.
Per-Patient Cost Comparison
Per-patient costs are the most commonly cited — and most misunderstood — metric in clinical trial budgeting. These figures include all direct patient-related costs: investigator fees, study coordinator fees, institutional fees, laboratory tests, imaging, patient stipends, and follow-up visits.
| Study Type | bioaccess® (LATAM) | US / EU |
|---|---|---|
| Simple device FIH (e.g., topical, implant) | $15K–$22K | $40K–$55K |
| Moderate complexity (e.g., vascular, orthopedic) | $22K–$30K | $55K–$65K |
| High complexity (e.g., cardiac, neuro) | $28K–$35K | $60K–$75K |
| Radiopharmaceutical (Lu-177, Ac-225) | $35K–$50K | $75K–$120K |
| Drug/biologic Phase I | $18K–$30K | $45K–$70K |
Ethics Approval Timeline Comparison
Timeline is often more valuable than cost savings. The ethics/IRB approval phase is typically the single largest bottleneck in study activation — and LATAM's advantage here is dramatic:
| Country / Region | Ethics Approval | Total Startup |
|---|---|---|
| El Salvador (DNM/CNEIS) | ~30 days (parallel) | 6–8 weeks |
| Panama (MINSA) | 3–5 weeks | 6–8 weeks |
| Colombia (INVIMA) | 4–6 weeks | 8–10 weeks |
| Mexico (COFEPRIS) | 4–8 weeks | 8–12 weeks |
| Brazil (ANVISA/CONEP) | 6–10 weeks | 10–14 weeks |
| United States (IRB) | 6–12 months | 12–18 months |
| European Union (EC) | 4–8 months | 10–16 months |
Total Study Cost: 10-Patient FIH Study
A 10-patient first-in-human study is the most common FIH design. Here's what it costs, all-in:
| Cost Category | bioaccess® (LATAM) | US / EU |
|---|---|---|
| CRO Management & Oversight | $80K–$120K | $150K–$250K |
| Site Fees (10 patients) | $150K–$300K | $400K–$750K |
| Regulatory & Ethics | $15K–$30K | $40K–$80K |
| Monitoring (CRA visits) | $25K–$45K | $60K–$120K |
| Data Management & EDC | $20K–$35K | $40K–$80K |
| Biostatistics & CSR | $15K–$25K | $30K–$60K |
| Insurance & Indemnity | $8K–$25K | $20K–$50K |
| Device Import & Logistics | $5K–$15K | N/A |
| Translations | $3K–$8K | N/A |
| Total | $321K–$603K | $740K–$1.39M |
**📊 Typical bioaccess® 10-Patient FIH: ~$350K**
Based on the median of our 50-company portfolio, a typical 10-patient FIH device study costs approximately $350,000 with bioaccess® — compared to $750K–$1.5M through a traditional US CRO.
Total Study Cost: 30-Patient Study
For larger feasibility or pivotal-supporting studies:
| Cost Category | bioaccess® (LATAM) | US / EU |
|---|---|---|
| CRO Management & Oversight | $120K–$200K | $250K–$450K |
| Site Fees (30 patients) | $450K–$900K | $1.2M–$2.25M |
| Regulatory & Ethics | $20K–$40K | $50K–$100K |
| Monitoring | $60K–$120K | $150K–$300K |
| Data Management & EDC | $35K–$60K | $70K–$140K |
| Biostatistics & CSR | $25K–$45K | $50K–$100K |
| Insurance & Logistics | $15K–$35K | $30K–$60K |
| Total | $725K–$1.4M | $1.8M–$3.4M |
Cost Breakdown by Category
Understanding where your money goes helps you make informed decisions about study design and country selection.
Site Fees
Site fees are the largest single cost category, typically representing 40-55% of total study costs. These include investigator compensation, study coordinator time, institutional overhead, pharmacy fees, laboratory services, and imaging. LATAM site fees are 50-65% lower than US equivalents due to lower labor costs and hospital fee structures.
Regulatory & Ethics Costs
Regulatory submission fees and ethics committee review fees in LATAM are dramatically lower than in the US. A typical INVIMA submission costs $3K-$8K; a COFEPRIS submission $4K-$10K. Compare this to $15K-$30K for a US IRB plus the cost of an IDE submission to FDA ($10K-$40K for the submission alone, plus regulatory consulting fees).
Monitoring & CRA Costs
Clinical Research Associate (CRA) day rates in LATAM run $800-$1,500/day compared to $2,000-$3,500/day in the US. bioaccess® uses ACRP-certified CRAs who conduct monitoring to the same ICH-GCP standards as US monitors, at significantly lower cost.
Data Management & Biostatistics
EDC setup, data cleaning, query management, and biostatistical analysis costs are 40-50% lower in LATAM. bioaccess® uses FDA-compliant electronic data capture systems (including Greenlight Guru Clinical) and employs biostatisticians experienced in FDA submission-ready clinical study reports.
Hidden Costs to Watch For
Transparency is essential. Here are LATAM-specific costs that some CROs fail to disclose upfront:
- Device import and customs clearance: $5K-$15K depending on device classification and country. Requires import permits from INVIMA, COFEPRIS, or the relevant regulatory agency.
- Clinical trial insurance: $8K-$25K per study. Most LATAM countries require sponsor-funded clinical trial insurance covering patient injuries. Costs vary by country and number of patients.
- Certified translations: $3K-$8K for protocol, informed consent, investigator brochure, and regulatory documents. All submissions must be in Spanish (or Portuguese for Brazil).
- International travel: $2K-$5K per monitoring trip for sponsors who want to observe procedures or conduct site visits. Budget 3-4 trips for a 10-patient study.
- Currency fluctuation risk: Minimal for dollarized economies (El Salvador, Panama) but relevant for Colombia (COP), Brazil (BRL), and Mexico (MXN). bioaccess® mitigates this through fixed-price contracts in USD.
- Re-export of unused devices: $2K-$5K if devices must be returned to the sponsor after study completion rather than destroyed locally.
**⚠️ Red Flag: CROs That Don't Disclose These Costs**
If a CRO's budget proposal doesn't include line items for insurance, device import, and translations, ask specifically. These are real costs that will appear eventually — it's better to know them upfront than to face budget overruns mid-study.
Get Your Personalized Estimate
These benchmarks provide directional guidance, but every study is unique. The bioaccess® Clinical Trial Calculator generates a personalized cost estimate based on your specific device type, therapeutic area, number of patients, and country preferences.
Open the Calculator
Request a Detailed Proposal